Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy

被引：18

作者：

Liu, Wei ^{[1
]}

Huang, Wenyang ^{[1
]}

Wang, Min ^{[1
]}

Lv, Rui ^{[1
]}

Li, Jian ^{[1
]}

Wang, Ying ^{[1
]}

Deng, Shuhui ^{[1
]}

Yi, Shuhua ^{[1
]}

Liu, Hong ^{[1
]}

Rao, Qing ^{[1
]}

Xu, Yingxi ^{[1
]}

Lv, Lulu ^{[2
]}

Qiu, Lugui ^{[1
]}

Zou, Dehui ^{[1
]}

Wang, Jianxiang ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, Beijing, Peoples R China

[2] Juventas Cell Therapy Ltd, Tianjin, Peoples R China

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 191卷 / 01期

关键词：

hepatitis B reactivation; anti-CD19 CAR T cell; B-cell lymphoma; chronic HBV infection; resolved HBV infection; CHEMOTHERAPY; RITUXIMAB;

D O I：

10.1111/bjh.16951

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：126 / 129

页数：5

共 8 条

[1] Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy [J].

Kusumoto, Shigeru ;

Arcaini, Luca ;

Hong, Xiaonan ;

Jin, Jie ;

Kim, Won Seog ;

Kwong, Yok Lam ;

Peters, Marion G. ;

Tanaka, Yasuhito ;

Zelenetz, Andrew D. ;

Kuriki, Hiroshi ;

Fingerle-Rowson, Gunter ;

Nielsen, Tina ;

Ueda, Eisuke ;

Piper-Lepoutre, Hanna ;

Sellam, Gila ;

Tobinai, Kensei .

BLOOD, 2019, 133 (02) :137-146

[2] Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial [J].

Locke, Frederick L. ;

Ghobadi, Armin ;

Jacobson, Caron A. ;

Miklos, David B. ;

Lekakis, Lazaros J. ;

Oluwole, Olalekan O. ;

Lin, Yi ;

Braunschweig, Ira ;

Hill, Brian T. ;

Timmerman, John M. ;

Deol, Abhinav ;

Reagan, Patrick M. ;

Stiff, Patrick ;

Flinn, Ian W. ;

Farooq, Umar ;

Goy, Andre ;

McSweeney, Peter A. ;

Munoz, Javier ;

Siddiqi, Tanya ;

Chavez, Julio C. ;

Herrera, Alex F. ;

Bartlett, Nancy L. ;

Wiezorek, Jeffrey S. ;

Navale, Lynn ;

Xue, Allen ;

Jiang, Yizhou ;

Bot, Adrian ;

Rossi, John M. ;

Kim, Jenny J. ;

Go, William Y. ;

Neelapu, Sattva S. .

LANCET ONCOLOGY, 2019, 20 (01) :31-42

[3] The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection [J].

Matsubara, Tokuhiro ;

Nishida, Tsutomu ;

Shimoda, Akiyoshi ;

Shimakoshi, Hiromi ;

Amano, Takahiro ;

Sugimoto, Aya ;

Takahashi, Kei ;

Mukai, Kaori ;

Yamamoto, Masashi ;

Hayashi, Shiro ;

Nakajima, Sachiko ;

Fukui, Koji ;

Inada, Masami .

ONCOLOGY LETTERS, 2017, 14 (06) :6543-6552

[4] Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis [J].

Mozessohn, L. ;

Chan, K. K. W. ;

Feld, J. J. ;

Hicks, L. K. .

JOURNAL OF VIRAL HEPATITIS, 2015, 22 (10) :842-849

[5] Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas [J].

Schuster, Stephen J. ;

Svoboda, Jakub ;

Chong, Elise A. ;

Nasta, Sunita D. ;

Mato, Anthony R. ;

Anak, Ozlem ;

Brogdon, Jennifer L. ;

Pruteanu-Malinici, Iulian ;

Bhoj, Vijay ;

Landsburg, Daniel ;

Wasik, Mariusz ;

Levine, Bruce L. ;

Lacey, Simon F. ;

Melenhorst, Jan J. ;

Porter, David L. ;

June, Carl H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (26) :2545-2554

[6] Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study [J].

Seto, Wai-Kay ;

Chan, Thomas S. Y. ;

Hwang, Yu-Yan ;

Wong, Danny Ka-Ho ;

Fung, James ;

Liu, Kevin Sze-Hang ;

Gill, Harinder ;

Lam, Yuk-Fai ;

Lie, Albert K. W. ;

Lai, Ching-Lung ;

Kwong, Yok-Lam ;

Yuen, Man-Fung .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) :3736-+

[7] Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma [J].

Wei, Jia ;

Zhu, Xiaojian ;

Mao, Xia ;

Huang, Liang ;

Meng, Fankai ;

Zhou, Jianfeng .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)

[8] Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection [J].

Yang, Hung-Chih ;

Tsou, Hsiao-Hui ;

Pei, Sung-Nan ;

Chang, Cheng-Shyong ;

Chen, Jia-Hong ;

Yao, Ming ;

Lin, Shyh-Jer ;

Lin, Johnson ;

Yuan, Quan ;

Xia, Ningshao ;

Liu, Tsang-Wu ;

Chen, Pei-Jer ;

Cheng, Ann-Lii ;

Hsu, Chiun .

JOURNAL OF HEPATOLOGY, 2018, 69 (02) :286-292

← 1 →